HK1024242A1 - New crystalline form of omeprazole - Google Patents

New crystalline form of omeprazole

Info

Publication number
HK1024242A1
HK1024242A1 HK00103546A HK00103546A HK1024242A1 HK 1024242 A1 HK1024242 A1 HK 1024242A1 HK 00103546 A HK00103546 A HK 00103546A HK 00103546 A HK00103546 A HK 00103546A HK 1024242 A1 HK1024242 A1 HK 1024242A1
Authority
HK
Hong Kong
Prior art keywords
methoxy
crystalline form
omeprazole
methylüsulfinylü
benzimidazole
Prior art date
Application number
HK00103546A
Other languages
English (en)
Inventor
Karin Lovqvist
David Noreland
Gunnel Sunden
Ingvar Ymen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27543202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1024242(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1024242A1 publication Critical patent/HK1024242A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK00103546A 1998-11-10 2000-06-13 New crystalline form of omeprazole HK1024242A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE29823393U DE29823393U1 (de) 1998-11-10 1998-11-10 Neue kristalline Form von Omeprazol
BR9816067-2A BR9816067A (pt) 1998-11-10 1998-11-10 Forma a de omeprazol, omeprazol, processo para a preparação da forma a de omeprazol, formulação farmacêutica, uso de omeprazol, e, método de tratamento de distúrbios gastrointestinais.
CA002363810A CA2363810A1 (en) 1998-11-10 1998-11-10 New form of omeprazole
EP98957255A EP0969819B1 (en) 1998-11-10 1998-11-10 New crystalline form of omeprazole
PCT/SE1998/002028 WO1999008500A2 (en) 1998-11-10 1998-11-10 New crystalline form of omeprazole
US10/076,225 US20020156284A1 (en) 1998-11-10 2002-02-13 Crystalline form of omeprazole

Publications (1)

Publication Number Publication Date
HK1024242A1 true HK1024242A1 (en) 2000-10-05

Family

ID=27543202

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00103546A HK1024242A1 (en) 1998-11-10 2000-06-13 New crystalline form of omeprazole

Country Status (34)

Country Link
US (3) US6150380A (da)
EP (2) EP0969819B1 (da)
JP (1) JP3457945B2 (da)
CN (1) CN1347413A (da)
AT (1) ATE233755T1 (da)
AU (1) AU756434B2 (da)
BR (1) BR9816067A (da)
CA (2) CA2284470C (da)
CZ (1) CZ301635B6 (da)
DE (3) DE69811868T2 (da)
DK (2) DK0969819T3 (da)
DZ (1) DZ2669A1 (da)
EE (1) EE04279B1 (da)
ES (1) ES2139559T3 (da)
FI (1) FI3873U1 (da)
GR (1) GR990300034T1 (da)
HK (1) HK1024242A1 (da)
HR (1) HRP20010281B1 (da)
HU (1) HUP0104379A3 (da)
IL (1) IL142703A0 (da)
IS (1) IS2025B (da)
MA (1) MA26574A1 (da)
NO (1) NO320014B1 (da)
NZ (1) NZ511377A (da)
PL (1) PL190870B1 (da)
PT (1) PT969819E (da)
RU (1) RU2207339C2 (da)
SI (1) SI0969819T1 (da)
SK (1) SK286562B6 (da)
TR (1) TR200101282T2 (da)
TW (1) TW533203B (da)
UA (1) UA72748C2 (da)
WO (1) WO1999008500A2 (da)
ZA (1) ZA9811174B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SI20019A (sl) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6750064B2 (en) * 2000-12-28 2004-06-15 S.S.C.I. Inc. Methods of screening for possible solid forms
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
US7855082B1 (en) 2001-10-31 2010-12-21 Astrazeneca Ab Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
EP1485373A1 (en) 2003-02-05 2004-12-15 Teva Pharmaceutical Industries Limited Method of stabilizing lansoprazole
WO2004080961A2 (en) * 2003-03-12 2004-09-23 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous solids of pantoprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005037424A1 (en) * 2003-10-06 2005-04-28 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
WO2006131338A2 (en) * 2005-06-08 2006-12-14 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
WO2007008588A2 (en) * 2005-07-07 2007-01-18 Dr. Reddy's Laboratories Ltd. Omeprazole form b
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
US8018588B2 (en) * 2007-06-06 2011-09-13 Aptuit, Inc. Sample holder and sample preparation device
US20090010388A1 (en) * 2007-06-06 2009-01-08 Stahly Barbara C Microplate and methods of using the same
US20090104236A1 (en) * 2007-10-18 2009-04-23 Pharmaceutics International, Inc. Pharmaceutical solid hybrids
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
CN102822166A (zh) * 2009-11-03 2012-12-12 葛兰素集团有限公司 制备5-脂氧合酶活化蛋白抑制剂及其中间体的方法
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
RU2501549C1 (ru) 2012-08-30 2013-12-20 Авва Девелопмент Лтд Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE69112917T2 (de) 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5714505A (en) * 1994-01-05 1998-02-03 Astra Aktiebolag Method for treatment of psoriasis, by omeprazole or related compounds
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9704183D0 (sv) 1997-11-14 1997-11-14 Astra Ab New process

Also Published As

Publication number Publication date
CA2363810A1 (en) 1999-02-25
AU1355199A (en) 1999-03-08
HRP20010281B1 (en) 2004-04-30
AU756434B2 (en) 2003-01-16
JP3457945B2 (ja) 2003-10-20
PL348247A1 (en) 2002-05-20
HUP0104379A2 (hu) 2002-04-29
RU2207339C2 (ru) 2003-06-27
ATE233755T1 (de) 2003-03-15
MA26574A1 (fr) 2004-12-20
NO20012286D0 (no) 2001-05-09
BR9816067A (pt) 2001-08-07
NO320014B1 (no) 2005-10-10
EP1221314A1 (en) 2002-07-10
US20020156284A1 (en) 2002-10-24
US6384059B1 (en) 2002-05-07
US6150380A (en) 2000-11-21
DZ2669A1 (fr) 2003-03-22
PL190870B1 (pl) 2006-02-28
ES2139559T3 (es) 2003-10-01
UA72748C2 (en) 2005-04-15
TW533203B (en) 2003-05-21
EE200100248A (et) 2002-10-15
WO1999008500A3 (en) 1999-07-29
DK199900074U1 (da) 2000-02-10
NO20012286L (no) 2001-07-03
EE04279B1 (et) 2004-04-15
SK286562B6 (sk) 2009-01-07
IL142703A0 (en) 2002-03-10
CA2284470A1 (en) 1999-02-25
FIU980578U0 (fi) 1998-12-21
WO1999008500A2 (en) 1999-02-25
PT969819E (pt) 2003-06-30
DE969819T1 (de) 2000-04-06
HRP20010281A2 (en) 2002-06-30
CZ301635B6 (cs) 2010-05-12
DE29823393U1 (de) 1999-05-27
FI3873U1 (fi) 1999-03-22
HUP0104379A3 (en) 2003-01-28
IS5935A (is) 2001-05-07
EP0969819B1 (en) 2003-03-05
CA2284470C (en) 2002-02-26
GR990300034T1 (en) 2000-07-31
EP0969819A2 (en) 2000-01-12
ZA9811174B (en) 2000-06-07
CZ20011611A3 (cs) 2002-01-16
DE69811868D1 (de) 2003-04-10
TR200101282T2 (tr) 2001-11-21
CN1347413A (zh) 2002-05-01
SK5452001A3 (en) 2001-11-06
DE69811868T2 (de) 2004-03-04
JP2001522780A (ja) 2001-11-20
IS2025B (is) 2005-08-15
NZ511377A (en) 2003-04-29
DK0969819T3 (da) 2003-05-19
SI0969819T1 (en) 2003-06-30
ES2139559T1 (es) 2000-02-16

Similar Documents

Publication Publication Date Title
HK1024242A1 (en) New crystalline form of omeprazole
SE9702483D0 (sv) New compound
CA2357744A1 (en) Potassium salt of (s)-omeprazole
CA2290963A1 (en) S-omeprazole magnesium trihydrate
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
MY118724A (en) New crystalline form of omeprazole
YU32301A (sh) Novi kristalni oblik omeprazola
MXPA05009183A (es) Polimorfos de s-omeprazol.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121110